IQVIA Holdings Inc.

The full register, from 13F filings

The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 1,056 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.

Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.

What a reader needs to know to read these numbers

• Holdings side found nothing to size or name. Searched the FY2025 10-K (filed 17 Feb 2026) and the Q2 2026 10-Q (filed 28 Jul 2026, period ended 30 Jun 2026) for 'equity method', 'unconsolidated', 'joint venture', 'investments in', 'non-marketable', 'strategic investment', 'noncontrolling interest', 'consideration for services', 'received equity', 'warrant', 'investee' and other terms. No named investee (biotech, health-tech, or otherwise) appears anywhere in either filing. Two combined, unnamed balance-sheet buckets exist: 'Investments in unconsolidated affiliates' ($390 million at 30 Jun 2026, $324 million at 31 Dec 2025, $266 million at 31 Dec 2024) and long-term 'Investments in debt, equity and other securities' ($82 million at 30 Jun 2026, $108 million at 31 Dec 2025). Neither the 10-K's dedicated Investments note (Note 4) nor the fair-value note names a single constituent investee, unlike Moody's CCXI/BitSight disclosures. Per the rule against assigning a combined balance to one investee, no holding is recorded for these buckets; the figures are left here and in unknowns instead.
• No evidence of equity taken as consideration for services (a pattern flagged as plausible for a CRO). Searched 'consideration for services', 'received equity', 'in exchange for services' and 'equity interest in a customer' in the 10-K; none found. IQVIA's revenue recognition and investments notes describe only cash-settled contracts, trading securities (mutual funds), factored receivables, and the equity-method/measurement-alternative buckets above.
• Q2 Solutions, once a 50/50 clinical-trial-laboratory joint venture between IQVIA and Quest Diagnostics Incorporated, is referenced only once in the FY2025 10-K, in an executive's biography, described as 'IQVIA Laboratories (formally known as Q2 Solutions, a joint venture between the Company and Quest Diagnostics Incorporated...)'. The rest of the 10-K refers only to 'IQVIA operates laboratories' with no joint-venture framing, and no equity-method investment, noncontrolling interest, or ownership percentage tied to Q2 Solutions/IQVIA Laboratories appears anywhere in the financial statements. This reads as a venture that has since been folded into IQVIA's own consolidated operations (name changed, structure no longer described as a JV), consistent with the brief's warning that a venture named in an older filing may have been fully acquired since. The filings checked do not, however, contain an explicit sentence confirming 100% ownership, so it is not listed as a $0/exited row; see unknowns.
• Clinical trial data, patient datasets, and customer/pharma contracts, however commercially valuable to IQVIA, are explicitly excluded from holdings: they are not equity stakes in another company and were not treated as such anywhere in this research.
• Private-equity/strategic-holder check (IQVIA's IMS Health side was taken private by TPG Capital and CPP Investment Board Private Holdings Inc. in 2010 before the 2016 Quintiles/IMS Health merger). The 2026 proxy's 5% stockholders table (as of 31 Jan 2026) lists only The Vanguard Group (12.4%), BlackRock, Inc. (8.9%) and Harris Associates L.P. (6.9%): no PE sponsor and no strategic holder. EDGAR's SC 13D/13G filer list for CIK 0001478242 shows the last SC 13D/A was filed 13 Aug 2019 by 'CPP Investment Board Private Holdings Inc.' (CIK 0001283718), by then down to 2.1% (4,101,285 shares of 195,894,501 then outstanding), with no 13D or 13G filed by that CIK since. The same CIK still appears in the routine 13F register, now at 0.76% (1,246,820 shares, Q2 2026), i.e. an ordinary passive institutional position, not a controlling stake; see the Canada Pension Plan Investment Board register row. TPG's board connection is Todd B. Sisitsky, a TPG partner, who per the 2026 proxy holds 0 IQVIA shares and does not participate in the non-employee director equity-compensation program 'due to his relationship with TPG, Inc.': no TPG fund position was found anywhere in the register or the 13D/13G history. Conclusion: no private-equity or strategic holder remains at reportable size; the pre-merger PE sponsors traced down to an immaterial, ordinary institutional position (CPPIB) and a zero personal stake (TPG, via Sisitsky).
• A third party not tied to the PE heritage was checked for completeness: GIC Private Limited (Singapore's sovereign wealth fund) filed a Schedule 13G on 15 Aug 2024 reporting 9,130,496 shares, 5.01% of 182,300,000 shares then outstanding. It is absent from the 2026 proxy's 5% table (Jan 2026) and no more recent 13G/13G-A has been filed by GIC for IQV, consistent with its position having fallen under the 5% reporting threshold at some point between Aug 2024 and Jan 2026 (IQVIA's share count fell from 182.3m to 164.6m over that period via buybacks, which alone would raise GIC's percentage if unchanged, so the drop implies GIC also sold shares). GIC's current size could not be verified in a 13F because sovereign wealth funds of GIC's type are not always required to (or do not) file Form 13F, and no fresher Schedule 13G/A was found; see unknowns.
• Vanguard reconciliation: the 2026 proxy cites a stale Schedule 13G figure of 21,077,827 shares (12.4%); the fresh Q2 2026 13F sweep across all 8 successor entities used in this file gives 20,152,585 shares (12.24%), about 925,000 shares lower. Per the chunk-prompt lesson on preferring the fresh 13F over a stale 13G quoted in a proxy, the 13F figure is used in the register row and the 13G figure is kept here as the reconciliation.
• company.shares_outstanding (164,600,000) is taken directly from the Q2 2026 10-Q cover page ('164.6 million shares outstanding as of July 21, 2026'), which matches the balance sheet's '164.6 shares outstanding as of June 30, 2026' (in millions). Both are rounded to one decimal place in the filing itself; no more precise figure was found in the filings searched. No stock split was found in the FY2025 10-K (searched 'stock split', 'forward split', 'reverse split': none found).
• IQVIA has a single class of common stock (par value $0.01, one vote per share); no dual-class or founder-control structure. Chairman and CEO Ari Bousbib is by far the largest insider holder (1.4% per the proxy) but well short of a controlling position.
• Self-gate, computed from this final file the way the chart computes it (member rows counted at full value, only the aggregate they roll into is reduced by their sum): non-aggregate rows are Vanguard 20,152,585 + BlackRock 14,549,693 + Harris Associates 12,183,830 + State Street 7,508,244 + JPMorgan 6,139,775 + Artisan Partners 4,743,434 + Geode 4,454,134 + Invesco 3,275,141 + CPPIB 1,246,820 + Bousbib 2,421,932 = 76,675,588. The aggregate row ('All executive officers and directors as a group') carries 2,982,890 raw shares, reduced by its one member (Bousbib, 2,421,932) to a residual of 560,958. Total = 76,675,588 + 560,958 = 77,236,546 shares, 46.92% of 164,600,000 shares outstanding. This is 11 register rows total. The percentage sits above the brief's typical 25-45% band but well under the 55% hard ceiling; it is explained by IQVIA's very large buyback program (259.6m shares issued against only 164.6m outstanding, 95.0m in treasury per the 10-Q) mechanically raising every unchanged institutional holder's percentage, plus an unusually large active holder (Harris Associates, 7.40%) and a full 8-entity Vanguard sweep, not by a mixed instrument, basis error, or double count.